Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis will present over 15 abstracts at the 2026 ASCO Annual Meeting, highlighting new data for its flagship drug CABOMETYX and its investigational asset zanzalintinib. Key presentations include new analyses from the Phase 3 CABINET trial in neuroendocrine tumors and the Phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Key figures
- Drug Name
- CABOMETYX (cabozantinib), zanzalintinib
- Phase Of Trial
- Phase 3 (CABINET, STELLAR-303, CheckMate-9ER, LITESPARK-033, MAIN-CAV); Phase 2 (RADICAL, CaboMain, EA3231, PEMBROCABOSARC, ZAMBONI, EXPLORE-RCC)
- Fda pdufa date
- December 3, 2026
- Presentation count
- 15+ abstracts
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.